CZEN 002
Alternative Names: (CKPV)2; MSH 11-13 DimerLatest Information Update: 09 Sep 2010
At a glance
- Originator Zengen
- Developer Abiogen Pharma
- Class Antifungals; Melanocyte-stimulating hormones; Peptides
- Mechanism of Action Alpha-MSH stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Mycoses; Ophthalmic infections; Periodontal disorders; Vulvovaginal candidiasis
Most Recent Events
- 22 Jun 2005 Clinical trials in Mycoses in USA (Intradermal)
- 22 Jun 2005 Phase-II clinical trials in Vulvovaginal candidiasis in Canada (Vaginal)
- 22 Jun 2005 Phase-II clinical trials in Vulvovaginal candidiasis in European Union (Vaginal)